TICKERNERD
Menu
SENSSENSHealthcare · Medical Devices

SENS Stock Forecast: Senseonics Holdings, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$9.51
−2.46% on the day

The 8 Wall Street analysts covering Senseonics Holdings, Inc. hold a median 12-month price target of $15 — +52.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 31 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$502.8M
Ticker Nerd rank
29/ 100
Median analyst target
$15
Analysts covering
8
Revenue$14.5M+117.8% y/y
Operating income−$36.0M
Net income−$36.7M
Free cash flow−$30.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+26.6%
1M
−6.5%
YTD
+72.3%
1Y
+31.9%
From 52W high
−8.0%
From 52W low
+95.7%
$5
$10
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SENS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Senseonics Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
29/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
64
Momentum
64
Size
52
Accruals
51
Growth
42
Quality
35
Value
26
Volatility
22
Issuance
9

Revisions (64): Analysts have, on balance, been raising their forecasts.

Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SENS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SENS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Jan 26Apr 26Jul 26Oct 26SENSHigh $18Median $15Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
4 Buy3 Hold1 Sell
Low $9Median $15High $18

The green dot is the last close — the median target sits +52.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 Oct 2026TD CowenReiteratesBuy—
7 Oct 2026BarclaysInitiatesEqual-Weight—
15 July 2026MizuhoMaintainsOutperform—
12 May 2026HC Wainwright & Co.MaintainsBuy—
11 May 2026StifelMaintainsHold—
6 Nov 2025HC Wainwright & Co.MaintainsBuy—
5 Nov 2025BarclaysMaintainsOverweight—
5 Nov 2025TD CowenMaintainsBuy—
27 Aug 2025BarclaysInitiatesOverweight—
15 July 2025TD CowenInitiatesBuy—
8 July 2025HC Wainwright & Co.MaintainsBuy—
10 Apr 2025MizuhoInitiatesOutperform—
5 Mar 2025HC Wainwright & Co.ReiteratesBuy—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
14 Aug 2024HC Wainwright & Co.ReiteratesBuy—
11 Mar 2024HC Wainwright & Co.ReiteratesBuy—
14 Nov 2023HC Wainwright & Co.ReiteratesBuy—
15 Aug 2023HC Wainwright & Co.MaintainsBuy—
19 July 2023JefferiesInitiatesUnderperform—
11 May 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

SENS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SENS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Senseonics Holdings, Inc. returned +31.9% against +12.4% for the S&P 500, dividends included.

SENS vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Jan 26Apr 26Jul 26Oct 26SENSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SENS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Senseonics Holdings, Inc. (SENS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.7×

Cheaper than 91% of US stocks

Price / sales
10.4×

Cheaper than 13% of US stocks

Price / book
5.6×

Cheaper than 17% of US stocks

EV / EBITDA
−4.0×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
117.8%

Higher than 93% of US stocks

Earnings growth (YoY)
—
Gross margin
59.1%

Higher than 72% of US stocks

Operating margin
−248.5%

Higher than 10% of US stocks

Net margin
−225.3%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−118.2%

Higher than 11% of US stocks

Return on assets
−41.4%

Higher than 10% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Senseonics Holdings, Inc. (SENS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Senseonics Holdings, Inc. has a market value of $502.8M and an enterprise value of $423.0M.

  • Revenue in the twelve months to 30 June 2026: $48.5M. The latest quarter grew 117.8% year on year.

  • Net income over the same four quarters: −$109.4M, a −225.3% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$96.8M, after $886K of capital spending.

  • Shares outstanding: 52.9M.

  • Trailing P/E: −5.7×; forward P/E: −4.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Senseonics Holdings, Inc. employs 130 people — $373K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 1 Nov 2026

Data provided by Twelve Data

Peers

SENS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
SENSSenseonics Holdings, Inc.$502.8M29
SGHTSight Sciences, Inc.$503.3M88
DCTHDelcath Systems, Inc.$484.7M96
RCELAVITA Medical, Inc.$484.0M71
TCMDTactile Systems Technology, Inc.$519.7M99
MASS908 Devices, Inc.$461.6M80
SSIISS Innovations International, Inc.$455.0M24

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Senseonics Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SENS news & analysis

Senseonics Initiates First-in-Human Study of Freedom, Designed to be the World's First CGM System with No On-body Component

GlobeNewsWire · 26 Oct 2026positive

Senseonics has initiated the first-in-human clinical evaluation of Freedom, an investigational transmitter-free continuous glucose monitoring system designed for one year of use and without an on-body component. The company cited a potential launch in 2028.

Why it matters — The study marks a milestone in Senseonics’ product-development roadmap for a potential future CGM system.

Senseonics Holdings, Inc. to Participate in Upcoming Investor Conferences

GlobeNewsWire · 22 Oct 2026neutral

Senseonics announced that management will participate in the Stifel 2026 Healthcare Conference in New York on November 10–12. Management will take part in a fireside chat at 3:20 p.m. ET and hold one-on-one investor meetings on November 10.

Why it matters — SENS watchers may note the scheduled opportunity for management to discuss the company with investors.

Senseonics Holdings, Inc. Schedules Third Quarter 2026 Earnings Release and Conference Call for November 9, 2026 at 4:30 P.M. Eastern Time

GlobeNewsWire · 21 Oct 2026neutral

Senseonics said it plans to release its third-quarter 2026 financial results after market close on November 9, 2026. The headline also schedules a conference call for that date at 4:30 p.m. Eastern Time.

Why it matters — The announcement gives SENS watchers the timing of the company’s quarterly results and related conference call.

Senseonics: Eversense 365 Adoption Has To Earn The Valuation

Seeking Alpha · 8 Oct 2026neutral

Seeking Alpha rates Senseonics Hold, citing sales growth, improving margins and Eversense 365’s product differentiation alongside adoption and funding risks. Recurring revenue depends on repeat implantations and wider prescriber uptake and insurance approval; high SG&A, dilution and negative free cash flow remain concerns.

Why it matters — SENS watchers may weigh recent growth and margin improvement against the execution and financing challenges that could affect Eversense 365 adoption.

Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal

Zacks Investment Research · 29 Sept 2026positive

Beta Bionics (BBNX) shares fell despite announcing a partnership integrating Senseonics' Eversense 365 continuous glucose monitor with its iLet automated insulin delivery system. The deal is expected to broaden CGM choice and strengthen BBNX's automated insulin delivery ecosystem across iLet and the upcoming Mint system.

Why it matters — The integration expands the commercial reach of Senseonics' Eversense 365 into automated insulin delivery platforms, potentially broadening its adoption among diabetes patients.

FAQ

Frequently asked questions about SENS stock

What is the SENS stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Senseonics Holdings, Inc. have a median 12-month price target of $15, with estimates ranging from $9 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SENS stock a buy right now?

Of the 8 analysts covering Senseonics Holdings, Inc., 4 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Senseonics Holdings, Inc. 29 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SENS?

As at 31 Oct 2026, Senseonics Holdings, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (64 of 100).

Will SENS stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +52.5% from the last close, and Ticker Nerd's factor model ranks Senseonics Holdings, Inc. 29 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SENS stock forecast for 2030?

No analyst covering Senseonics Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SENS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $18 over the next 12 months.

How has SENS stock performed over the past year?

Senseonics Holdings, Inc. returned +31.9% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Senseonics Holdings, Inc. do?

Senseonics Holdings Inc. is a medical technology company focused on long-term implantable continuous glucose monitoring systems for people with diabetes.

What is the latest news on SENS?

The most recent item we track (GlobeNewsWire, 26 Oct 2026): "Senseonics Initiates First-in-Human Study of Freedom, Designed to be the World's First CGM System with No On-body Component". Senseonics has initiated the first-in-human clinical evaluation of Freedom, an investigational transmitter-free continuous glucose monitoring system designed for one year of use and without an on-body component. The company cited a potential launch in 2028.

Company

About Senseonics Holdings, Inc.

Senseonics Holdings Inc. is a medical technology company focused on long-term implantable continuous glucose monitoring systems for people with diabetes. Its Eversense product line combines a small under-the-skin sensor, a removable smart transmitter, and a mobile app to provide ongoing glucose readings, alerts, and diabetes management support. The company’s current offerings are designed to serve patients and healthcare providers seeking an alternative to traditional short-duration CGM devices, with products used in the United States and international markets. Senseonics Holdings Inc. operates in the diabetes management and implantable medical device segments, where it plays a specialized role in glucose monitoring technology. Headquartered in Germantown, Maryland, the company is known for its focus on durable, wearable-connected monitoring solutions that support day-to-day diabetes care.

CEO Dr. Timothy T. Goodnow Ph.D. · 130 employees · United States · https://www.senseonics.com